8-K: InMed Pharmaceuticals Secures $10 Million Standby Equity Purchase Agreement with YA II PN, LTD

InMed Pharmaceuticals has entered into a standby equity purchase agreement with YA II PN, LTD, providing the company with access to up to $10 million in funding.

Summary

• InMed Pharmaceuticals has entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD, an investment fund managed by Yorkville Advisors Global LP.
• The agreement allows InMed to sell up to $10 million of its common shares to the investor over a 36-month period.
• The timing and amount of share sales are at InMed's discretion, with no obligation to sell any shares.
• The purchase price for shares will be 97% of the lowest daily volume-weighted average price (VWAP) during a three-day pricing period following an advance notice.
• InMed can set a minimum acceptable price for share issuances.
• The total number of shares issued is capped at 19.99% of the outstanding shares as of the agreement date, unless certain pricing conditions are met.
• The investor's beneficial ownership is limited to 9.99% of the outstanding shares.
• InMed paid a $25,000 structuring fee and will pay a commitment fee of 2.5% of the total commitment amount, with 25% paid in cash and the remaining 75% paid in quarterly installments in cash or shares.
• The agreement will automatically terminate on the earlier of January 1, 2027, or when the investor has purchased the full $10 million commitment amount.
• InMed can terminate the agreement with five business days' notice if no outstanding share issuances are pending.

Sentiment

Score: 7

Explanation: The document is generally positive as it secures funding for the company, but there are some potential negatives such as dilution and the cost of the commitment fee. The agreement is a standard financing mechanism for companies of this size and stage.

Positives

• The SEPA provides InMed with flexible access to capital, allowing them to raise funds as needed.
• The agreement extends InMed's financial runway, supporting the acceleration of their pharmaceutical programs and business development initiatives.
• InMed retains control over the timing and amount of share sales.
• The agreement includes a mechanism for setting a minimum acceptable price for share issuances, protecting the company from selling shares at undesirable prices.
• The agreement allows for termination by InMed with five business days' notice, providing flexibility.

Negatives

• The total number of shares that can be issued under the SEPA is limited to 19.99% of the outstanding shares, which could limit the total proceeds available to InMed.
• The investor's beneficial ownership is capped at 9.99%, which may limit the amount of capital that can be raised.
• The share price is set at 97% of the market price, which could result in a discount for the company.
• The agreement includes a commitment fee of 2.5% of the total commitment amount, which is an additional cost for InMed.

Risks

• The actual sales of shares under the SEPA will depend on market conditions and InMed's funding needs, and there is no guarantee that the full $10 million will be raised.
• The issuance of shares under the SEPA could lead to dilution for existing shareholders.
• The agreement is subject to the effectiveness of a registration statement with the SEC, which could delay the availability of funds.
• The agreement contains various conditions that must be met for the investor to purchase shares, and failure to meet these conditions could impact the availability of funds.

Future Outlook

InMed intends to use the proceeds from the SEPA for working capital and general corporate purposes, with the flexibility to raise capital as needed to support its pharmaceutical programs and business development initiatives. The company believes this agreement provides an extended financial runway.

Management Comments

• Eric A. Adams, Chief Executive Officer of InMed, stated that the equity facility is a key component of their financing strategy, offering flexibility and an extended runway.
• Adams also expressed confidence that Yorkville Advisors will be a valuable financial partner for their continued growth.

Industry Context

This agreement is a common financing method for small-cap pharmaceutical companies, providing access to capital without the need for traditional debt financing. It allows InMed to maintain control over the timing and amount of capital raised, which is beneficial in the volatile biotech sector. This type of agreement is often used by companies with ongoing research and development needs.

Comparison to Industry Standards

• Standby equity purchase agreements are a relatively common financing tool for small to mid-cap biotech companies, such as InMed, that need flexible access to capital.
• The terms of this agreement, such as the 97% of VWAP purchase price and the 2.5% commitment fee, are within the typical range for these types of agreements.
• Similar companies like Amyris and Cassava Sciences have used similar financing structures to raise capital.
• The 19.99% cap on share issuance is a common feature to avoid triggering shareholder approval requirements under Nasdaq rules.
• The 9.99% ownership limitation for the investor is also a standard clause to prevent the investor from gaining control of the company.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Employees may benefit from the increased financial stability and growth potential of the company.
• Customers may benefit from the continued development of InMed's pharmaceutical programs.
• Creditors may view the agreement positively as it strengthens the company's financial position.

Next Steps

• InMed will need to file a registration statement with the SEC to enable the sale of shares under the SEPA.
• InMed will decide on the timing and amount of share sales based on market conditions and their funding needs.
• The company will need to manage the potential dilution of existing shareholders.
• InMed will need to monitor the investor's ownership to ensure it does not exceed the 9.99% limit.

Key Dates

Keywords

Standby Equity Purchase Agreement, SEPA, equity financing, YA II PN, LTD, Yorkville Advisors Global LP, common shares, dilution, capital raise, pharmaceutical, funding